Table 1.

Correlation of expression and methylation of NEFL gene with cisplatin sensitivity in HNC cell lines

Cell linesNEFL expressionNEFL methylationCisplatin IC50 value, μmol/LCisplatin sensitivity
Hacat+UMNot determinedUnknown
PCI13+UM0.54S
O29+UM1S
HN17B+UM1.4S
HN22A+UM1.6S
O12+UM1.7S
HN38PM2MR
O13+PM2.25MR
SCC25+UM2.5MR
O11M2.65MR
O22+UM4.7MR
PCI51M6.5R
FaduM7R
SCC25cpM9.5R
HN17BcpPM9.6R
O28M18.45R

NOTE: Expression of NEFL was detected by real-time quantitative reverse transcriptase PCR with GAPDH as a normalization control. Abundant expression was recorded as + and no or reduced expression as −. NEFL methylation was analyzed by MSP and bisulfite DNA sequencing. Cisplatin IC50 value was determined by 72-hour treatment of individual cell lines with cisplatin. Cisplatin sensitivity of the cell lines was categorized into sensitive (IC50 < 2 μmol/L), moderately resistant (IC50 = 2–5 μmol/L), and resistant (IC50 > 5 μmol/L).

Abbreviations: M, methylated; MR, moderately resistant; PM, partial methylation; R, resistant; S, sensitive; UM, unmethylated.